PDCD1 and neoplasm: The Estimating the Proportion of Immune and Cancer cells (EPIC) analysis showed decreased numbers of endothelial cells in good responders to anti-PD1 therapy (Figure S3D), implicating increased frequency of endothelial cells in pro-angiogenesis and tumor progression [26,27].